Genfit throws in the towel on NASH, exiting a tumultuous field full of bright market prospects and lethal R&D setbacks
Genfit has had enough of NASH.
The French biotech $GNFT says it’s looked at its failed Phase III from every angle, and sees no need …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
